Skip to main content
Clinical Trials/NCT03350516
NCT03350516
Completed
Phase 3

Demonstrating Non-inferiority of Lower Dose Calcium Supplementation During Pregnancy for Reducing Preeclampsia and Neonatal Outcomes

Harvard School of Public Health (HSPH)3 sites in 2 countries22,000 target enrollmentNovember 30, 2018

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Pregnancy Related
Sponsor
Harvard School of Public Health (HSPH)
Enrollment
22000
Locations
3
Primary Endpoint
Proportion of preterm birth
Status
Completed
Last Updated
last year

Overview

Brief Summary

The World Health Organization currently recommends that pregnant women in populations with low calcium intake receive daily calcium supplementation (1500 - 2000 mg) divided into three doses which are preferably taken at mealtimes, in addition to daily iron folic-acid supplements. Despite proven efficacy and the WHO recommendation, calcium supplementation in pregnancy is not standard of care in the vast majority of low-income and middle-income countries. Two important barriers to implementation are the cost of the supplements and complexity of the suggested calcium dosing schedule. A lower dose of calcium (500 mg) administered as a single dose has been shown to be beneficial in several trials, and if found to be as effective as the 1500 mg supplementation regimen, it may help overcome these barriers and increase individual and health system adoption.

The Investigators will conduct two parallel, individually randomized, double blind non-inferiority trials in India and Tanzania. Participating pregnant woman will be randomized to either 1500 mg or 500 mg calcium supplementation. The India and Tanzania trials are independently powered for the primary outcomes of i) preeclampsia and ii) preterm birth. The India and Tanzania sites will each enroll 11,000 participants.

Registry
clinicaltrials.gov
Start Date
November 30, 2018
End Date
December 16, 2022
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
Harvard School of Public Health (HSPH)
Responsible Party
Principal Investigator
Principal Investigator

Wafaie Fawzi

Richard Saltonstall Professor of Population Sciences, Professor of Nutrition, Epidemiology, and Global Health, Chair of the Department of Global Health and Population

Harvard School of Public Health (HSPH)

Eligibility Criteria

Inclusion Criteria

  • Nulliparous
  • Attending first ANC visit at study clinics
  • Pregnant women \<20 weeks
  • ≥ 18 years old
  • Intending to stay in study area until 6 weeks post delivery
  • Provides informed consent

Exclusion Criteria

  • History or signs and/or symptoms of nephrolithiasis
  • Prior diagnosis of parathyroid disorder or thyroidectomy
  • Diseases that require digoxin, phenytoin, or tetracycline therapy

Outcomes

Primary Outcomes

Proportion of preterm birth

Time Frame: Birth

Proportion of pregnant women with incident preeclampsia

Time Frame: Gestational week 20 to Delivery

Study Sites (3)

Loading locations...

Similar Trials